Articles
DOI DOI: 10.62441/actainnovations.v63i.1366

UMBILICAL CORD–DERIVED MESENCHYMAL STEM CELLS (UC-MSC) THERAPY USING THE VINSKI PROTOCOL IN A STRUCTURED CARE PATHWAY FOR REFRACTORY AUTOIMMUNE DISEASE: A PROSPECTIVE SINGLE-CENTRE OBSERVATIONAL CASE SERIES

Deby Susanti Pada Vinski 1, Svetlana Trofimova 2, Markus Wibowo 3, Natasha Cinta Vinski4, Andi Kurniawan Nugroho 5
  1. 1 PhD, Celltech Stem Cell Centre Laboratory and Banking, Jakarta, Indonesia.
  2. 2 PhD, Institute of Bioregulation and Gerontology, St. Petersburg, Russia.
  3. 3 National Defense Central Hospital (RSPPN) Panglima Besar Soedirman, Indonesia.
  4. 4 Universitas Hasanuddin Makassar, Indonesia.
  5. 5 Universitas Semarang, Semarang, Indonesia.

Abstract

Mesenchymal stem cells, particularly those that are umbilical cord-derived, are a stem cell therapy approach with immunomodulatory potential in addressing autoimmune disease as a major cause of chronic disability and morbidity. An integrated multi-system mesenchymal stem cells treatment program employed a multi-system, cross-domain customization approach referred to as the Vinski protocol, which combined closed-system umbilical cord-derived mesenchymal stem cells therapy with complementary, individualized clinical strategies. A single tertiary regenerative medicine center served as the research site for this prospective observational case series (Celltech Stem Cell Centre in South Jakarta, Indonesia). The sample consisted of adult patients with refractory autoimmune disease. Each patient received one or more therapy cycles. Most patients were previously exposed to conventional treatments. Umbilical cord-derived mesenchymal stem cells were manufactured from screened allogeneic umbilical cord tissue using a good manufacturing practice-aligned closed system. Outcomes were defined as the change in disease-specific activity indices and patient-reported outcomes. Measurements were taken at baseline and at three, six, and 12 months. Secondary outcome measures were collected to assess steroid-sparing effects, inflammatory biomarkers, and safety. The therapy resulted in clinically meaningful reductions in disease activity scores, improved fatigue and pain scores, and decreased oral corticosteroid requirements in a significant proportion of patients. No therapy-related serious adverse events, neoplasia, or opportunistic infections were observed during the follow-up window. In this single-site study, umbilical cord-derived mesenchymal stem cells therapy delivered within a structured multidisciplinary care pathway was safe and feasible and resulted in relief of symptoms for adults with refractory autoimmune disease. Definitive conclusions will require controlled trials, but this research contributes to the rationale and the potential of this clinical protocol and its multi-system, system-wide interventions based on a framework of customization to needs. Customized co-interventions to facilitate optimal UC-MSC therapy, per the Vinski protocol, can represent a novel approach that advances the science and theory of the treatment of refractory autoimmune diseases. The treatment approach, therefore, warrants continued research.

How to Cite

Vinski , D. S. P., Trofimova , S., Wibowo , M., Vinski, N. C., & Nugroho , A. K. (2026). UMBILICAL CORD–DERIVED MESENCHYMAL STEM CELLS (UC-MSC) THERAPY USING THE VINSKI PROTOCOL IN A STRUCTURED CARE PATHWAY FOR REFRACTORY AUTOIMMUNE DISEASE: A PROSPECTIVE SINGLE-CENTRE OBSERVATIONAL CASE SERIES. ACTA INNOVATIONS, 63, 1181–1189. https://doi.org/10.62441/actainnovations.v63i.1366
Endnote/Zotero/Mendeley (RIS) BibTeX

References

  1. 1. Bakinowska, E., Bratborska, A. W., Kiełbowski, K., Ćmil, M., Biniek, W. J., & Pawlik, A. (2024). The role of mesenchymal stromal cells in the treatment of rheumatoid arthritis. Cells, 13(11), Article 915. https://doi.org/10.3390/cells13110915
  2. 2. Barber, M. R. W., Drenkard, C., Falasinnu, T., Hoi, A., Mak, A., Kow, N. Y., Svenungsson, E., Peterson, J., & Clarke, A. E. (2021). Global epidemiology of systemic lupus erythematosus. Nature Reviews Rheumatology, 17(9), 515–532. https://doi.org/10.1038/s41584-021-00668-1
  3. 3. Cao, Z., Wang, D., Jing, L., Wen, X., Xia, N., Ma, W., Zhang, X., Jin, Z., Shen, W., Yao, G., Chen, W., Tang, X., Geng, L., Li, H., Li, X., Ding, S., Liang, J., Feng, X., Zhang, H., Liu, S., … Sun, L. (2023). Allogenic umbilical cord-derived mesenchymal stromal cells sustain long-term therapeutic efficacy compared with low-dose interleukin-2 in systemic lupus erythematosus. Stem Cells Translational Medicine, 12(7), 431–443. https://doi.org/10.1093/stcltm/szad032
  4. 4. Charmaz, K. (2014). Constructing grounded theory (2nd ed.). SAGE.
  5. 5. Chen, Y., Li, X., Zhang, J., Peng, J., Huang, F., Bao, J., Fan, Y., & Huang, S. (2025). Global clinical trials on stem cell therapy for autoimmune diseases: Trends and future directions. Frontiers in Immunology, 16, Article 1616231. https://doi.org/10.3389/fimmu.2025.1616231
  6. 6. Corbin, J., & Strauss, A. (2015). Basics of qualitative research: Techniques and procedures for developing grounded theory (4th ed.). SAGE.
  7. 7. Damiani, G., Bragazzi, N. L., Karimkhani Aksut, C., Wu, D., Alicandro, G., McGonagle, D., Guo, C., Dellavalle, R., Grada, A., Wong, P., La Vecchia, C., Tam, L.-S., Cooper, K. D., & Naghavi, M. (2021). The global, regional, and national burden of psoriasis: Results and insights from the Global Burden of Disease 2019 Study. Frontiers in Medicine, 8, Article 743180. https://doi.org/10.3389/fmed.2021.743180
  8. 8. Ding, M., Jin, L., Cui, S., Yang, L., He, J., et al. (2025). Human umbilical cord mesenchymal stem cells for the treatment of systemic lupus erythematosus via glucose metabolism of CD4+ T cells. Stem Cell Reviews and Reports, 21(4), 1013–1033. https://doi.org/10.1007/s12015-025-10848-1
  9. 9. Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J. N., Cervera, R., Doria, A., Gordon, C., Govoni, M., Houssiau, F., Jayne, D., Kouloumas, M., Kuhn, A., Larsen, J. L., Lerstrøm, K., Morand, E., Mosca, M., Schneider, M., … Boumpas, D. T. (2019). 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 78(6), 736–745. https://doi.org/10.1136/annrheumdis-2019-215089
  10. 10. Figueroa, F. E., Carrión, F., Villanueva, S., & Khoury, M. (2012). Mesenchymal stem cell treatment for autoimmune diseases: A critical review. Biological Research, 45(3), 269–277. https://doi.org/10.4067/S0716-97602012000300008
  11. 11. Fraenkel, L., Bathon, J. M., England, B. R., St. Clair, E. W., Arayssi, T., Carandang, K., Deane, K. D., Genovese, M. C., Huston, K. K., Kerr, G. S., Kremer, J. M., Lenert, A., Liew, J. W., O’Dell, J. R., Park, G. S., Peden, D., Suter, L., Smith, B. J., Turgunbaev, M., … Singh, J. A. (2021). 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care & Research, 73(7), 924–939. https://doi.org/10.1002/acr.24596
  12. 12. GBD 2021 Rheumatoid Arthritis Collaborators. (2023). Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: A systematic analysis of the Global Burden of Disease Study 2021. The Lancet Rheumatology, 5(10), e594–e610. https://doi.org/10.1016/S2665-9913(23)00211-4
  13. 13. Glaser, B. G., & Strauss, A. L. (1967). The discovery of grounded theory: Strategies for qualitative research. Aldine.
  14. 14. Han, X., Liao, R., Li, X., et al. (2025). Mesenchymal stem cells in treating human diseases: Molecular mechanisms and clinical studies. Signal Transduction and Targeted Therapy, 10, Article 262. https://doi.org/10.1038/s41392-025-02313-9
  15. 15. Hwang, J. J., Rim, Y. A., & Ju, J. H. (2021). Recent developments in clinical applications of mesenchymal stem cells in osteoarthritis and rheumatoid arthritis. Frontiers in Immunology, 12, Article 631291. https://doi.org/10.3389/fimmu.2021.631291
  16. 16. Jasim, S. A., Yumashev, A. V., Abdelbasset, W. K., Margiana, R., Markov, A., Suksatan, W., ... & Ahmadi, S. H. (2022). Shining the light on the clinical application of mesenchymal stem cell therapy in autoimmune diseases. Stem Cell Research & Therapy, 13(1), Article 101. https://doi.org/10.1186/s13287-022-02782-7
  17. 17. Mesa, L. E., López, J. G., López Quiceno, L., Barrios Arroyave, F., Halpert, K., & Camacho, J. C. (2023). Clinical efficacy and safety of mesenchymal stem cells for rheumatoid arthritis: A systematic review and meta-analysis. PLoS ONE, 18(7), Article e0284828. https://doi.org/10.1371/journal.pone.0284828
  18. 18. Munir, H., & McGettrick, H. M. (2015). Mesenchymal stem cell therapy for autoimmune disease: risks and rewards. Stem Cells and Development, 24(18), 2091–2100. https://doi.org/10.1089/scd.2015.0008
  19. 19. Pignatti, E., Maccaferri, M., Chiesa, S., & Bortoluzzi, A. (2024). A comprehensive review on the role of mesenchymal stromal/stem cells in the management of rheumatoid arthritis. Expert Review of Clinical Immunology, 20(5), 463–484. https://doi.org/10.1080/1744666X.2023.2299729
  20. 20. Ren, S., Hu, J., Chen, Y., Yuan, T., Hu, H., & Li, S. (2016). Human umbilical cord-derived mesenchymal stem cells promote interleukin-17 production from human peripheral blood mononuclear cells of healthy donors and systemic lupus erythematosus patients. Clinical and Experimental Immunology, 183(3), 389–396. https://doi.org/10.1111/cei.12737
  21. 21. Ruan, G., Sun, Y., Yu, Z., Bai, X., Yang, H., & Qian, J. (2025). Global, regional, and national burden of inflammatory bowel disease from 1990 to 2021: Findings from the Global Burden of Disease 2021. Gastroenterology Report, 13, Article goaf082. https://doi.org/10.1093/gastro/goaf082
  22. 22. Safiri, S., Kolahi, A.-A., Cross, M., Carson-Chahhoud, K., Hoy, D., Almasi-Hashiani, A., et al. (2019). Prevalence, incidence, and years lived with disability due to rheumatoid arthritis and its attributable risk factors, 1990–2017: Results from the Global Burden of Disease Study 2017. Annals of the Rheumatic Diseases, 78(11), 1463–1471. https://doi.org/10.1136/annrheumdis-2019-215920
  23. 23. Smolen, J. S., Landewé, R. B. M., Bergstra, S. A., Kerschbaumer, A., Sepriano, A., Aletaha, D., Caporali, R., Edwards, C. J., Hyrich, K. L., Pope, J. E., de Souza, S., Stamm, T. A., Takeuchi, T., Verschueren, P., & van der Heijde, D. (2023). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the Rheumatic Diseases, 82(1), 3–18. https://doi.org/10.1136/ard-2022-223356
  24. 24. Vinski, D. S. P., Quintosa, J. R., Hajar, A. I., Vinski, N. C., & Nugroho, A. K. (2025). Advancements in stem cell therapy for pulmonary fibrosis: A comprehensive review with Vinski protocol. Journal of World Science, 4(9), 698–705. https://doi.org/10.58344/jws.v4i9.1503
  25. 25. World Medical Association. (2013). World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA, 310(20), 2191–2194. https://doi.org/10.1001/jama.2013.281053
  26. 26. Yordanova, A., et al. (2024). Umbilical cord mesenchymal stem cell secretome modulates B-cell activation and antigen presentation in systemic lupus erythematosus. International Journal of Molecular Sciences, 25(23), Article 12515. https://doi.org/10.3390/ijms252312515
  27. 27. Zeng, L., Yang, K., Yu, G., Chen, J., Long, Z., Xiang, W., Liu, S., Zheng, Y., Yan, Y., Hao, M., Sun, L. (2024). Efficacy and safety of culture-expanded mesenchymal stromal cell therapy in the treatment of 4 types of inflammatory arthritis: A systematic review and meta-analysis of 36 randomized clinical trials of mesenchymal stem cells for inflammatory arthritis. Seminars in Arthritis and Rheumatism, 68, Article 152498. https://doi.org/10.1016/j.semarthrit.2024.152498